NCT02844309

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance therapy.

Detailed description

Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and dexamethasone. if a partial remission response or better is achieved, thalidomide plus prednisone maintenance therapy will be given for no more than two years.

Conditions

• Waldenström Macroglobulinemia

Interventions

Type	Name	Description
DRUG	Thalidomide	thalidomide 50-150 mg per night

Timeline

• Start date: 2016-05-01
• Primary completion: 2019-11-01
• Completion: 2020-05-01
• First posted: 2016-07-26
• Last updated: 2026-02-11

Locations

1 site across 1 country: China